All In Biotech

NDA 018240 · Twi Pharms

Tenormin

Atenolol · Oral · beta-Adrenergic Blocker

Novel

Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Aug 19, 1981

Approved uses

4

Original approval plus efficacy supplements

Registered trials

122

29 Phase 3, 7 recruiting

FAERS reports

133,241

93,431 serious, 11,331 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2025.

INDICATIONS AND USAGE Hypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 1990 Supplement 13 · Efficacy
  • Sep 13, 1989 Supplement 5 · Efficacy
  • Sep 4, 1985 Supplement 2 · Efficacy
  • Aug 19, 1981 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • TENORMIN · ATENOLOL 25MG · TABLET, ORAL · Prescription · TE AB
  • TENORMIN · ATENOLOL 100MG · TABLET, ORAL · Prescription · TE AB
  • TENORMIN · ATENOLOL 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Atenolol" as an intervention, any sponsor and status, largest first.

All 122 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8,061
  • nausea7,924
  • fatigue7,694
  • diarrhoea7,124
  • dyspnoea6,387
  • dizziness6,333
  • headache5,989
  • pain5,767
  • asthenia5,012
  • fall4,728
  • arthralgia4,669
  • malaise4,305

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044,208
20054,818
20064,685
20074,035
20084,456
20095,158
20106,629
20116,664
20127,429
20136,456
20148,239
20159,678
20169,111
20178,094
20188,469
20197,496
20206,223
20214,826
20224,230
20233,598
20243,327
20253,211
20262,195

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tenormin (Atenolol)

2024 spending

$3.1M

Beneficiaries

606

2,584 claims

Per beneficiary

$5,079

$12.57 per unit

View as table
YearSpending
2020$4,942,434
2021$4,388,570
2022$4,125,527
2023$3,536,522
2024$3,077,659

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,175 on PubMed

Sponsor: Twi Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.